Compare YHGJ & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHGJ | RLMD |
|---|---|---|
| Founded | 1975 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 661.9M |
| IPO Year | 2006 | 2012 |
| Metric | YHGJ | RLMD |
|---|---|---|
| Price | $2.91 | $6.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 3.9K | ★ 2.4M |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,705,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.76 | ★ 154.83 |
| 52 Week Low | $0.47 | $0.55 |
| 52 Week High | $10.29 | $8.00 |
| Indicator | YHGJ | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 47.43 |
| Support Level | $2.56 | $6.17 |
| Resistance Level | $3.11 | $7.34 |
| Average True Range (ATR) | 0.15 | 0.43 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 0.00 | 42.59 |
Yunhong Green CTI Ltd develops, produces, distributes, and sells consumer products in the United States and several other countries, and manufactures film products for commercial and industrial use in the United States. The Company focuses on flexible film technologies and has developed products utilizing flexible films, including novelty balloons, pouches, and films for packaging applications. Its principal product lines include foil and latex balloons and related gift items, and flexible films for food and other packaging uses. It also assembles balloon-inspired gift items, including small gift bouquets with ribbons and/or a foil balloon, and holds patents related to flexible films, including films, zipper closures, valves, and other features.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.